Sanara MedTech Inc (SMTI)

NASD · Healthcare · Medical Instruments & Supplies · USA

Sanara MedTech Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Instruments & Supplies industry.

Sanara MedTech develops and commercializes surgical solutions for wound care and bone repair. Its main offerings include CellerateRX Surgical, a collagen-based product for managing surgical wounds, and BIASURGE, an antimicrobial irrigation solution, alongside bone matrix products like BiFORM and ALLOCYTE Plus. The company distributes these products to hospitals and surgical centers throughout the United States.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Sanara MedTech Inc stock.

Our verdict on SMTI

Overvalued: intrinsic value $11.93 per share, market price $32.73, margin of safety -174.4% (as of 2026-11-17).

Discounting its cash flows at 9.8% (average of 2 methods) values the shares at $11.93; the price of $32.73 is 174% above that value, and 75% of that value comes from beyond year five.

ETFs with the most weight in SMTI

14 more funds hold it; the full list is part of the paid plan.

More on SMTI

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than SMTI in Medical Instruments & Supplies

13 more in this industry show a wider margin of safety.

Is SMTI undervalued or overvalued?

SMTI is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 9.8% (average of 2 methods) values the shares at $11.93; the price of $32.73 is 174% above that value, and 75% of that value comes from beyond year five.

What is the intrinsic value of SMTI?

$11.93 per share (as of the 2026-11-17 close), against a market price of $32.73. That is a margin of safety of -174.4%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.